1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Left Ventricular Dysfunction - Pipeline Review, H1 2016

Left Ventricular Dysfunction - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 56 pages

Left Ventricular Dysfunction - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Left Ventricular Dysfunction - Pipeline Review, H1 2016’, provides an overview of the Left Ventricular Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction
- The report reviews pipeline therapeutics for Left Ventricular Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Left Ventricular Dysfunction therapeutics and enlists all their major and minor projects
- The report assesses Left Ventricular Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Left Ventricular Dysfunction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Left Ventricular Dysfunction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Left Ventricular Dysfunction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Left Ventricular Dysfunction - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Left Ventricular Dysfunction Overview 6
Therapeutics Development 7
Pipeline Products for Left Ventricular Dysfunction - Overview 7
Left Ventricular Dysfunction - Therapeutics under Development by Companies 8
Left Ventricular Dysfunction - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Left Ventricular Dysfunction - Products under Development by Companies 12
Left Ventricular Dysfunction - Companies Involved in Therapeutics Development 13
Amgen Inc. 13
Bayer AG 14
Capricor Therapeutics, Inc. 15
Innopharmax Inc. 16
RedHill Biopharma Ltd. 17
TiGenix NV 18
Left Ventricular Dysfunction - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
BAY-1142524 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
CAP-1001 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
CAP-1002 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
carvedilol CR - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
carvedilol phosphate CR - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
CTX-101 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
omecamtiv mecarbil MR - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Left Ventricular Dysfunction - Recent Pipeline Updates 39
Left Ventricular Dysfunction - Dormant Projects 49
Left Ventricular Dysfunction - Discontinued Products 50
Left Ventricular Dysfunction - Product Development Milestones 51
Featured News and Press Releases 51
Aug 27, 2013: Amgen to Highlight New Data at Upcoming ESC Congress 2013 51
Jun 18, 2013: Cytokinetics Announces Presentation Of Results From Phase IIb Clinical Trial Of Omecamtiv Mecarbil At ESC Congress 2013 52
Feb 19, 2013: RedHill Biopharma Announces Notice Of Allowance From US Patent And Trademark Office For Cardio Drug RHB-101 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables
Number of Products under Development for Left Ventricular Dysfunction, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Left Ventricular Dysfunction - Pipeline by Amgen Inc., H1 2016 13
Left Ventricular Dysfunction - Pipeline by Bayer AG, H1 2016 14
Left Ventricular Dysfunction - Pipeline by Capricor Therapeutics, Inc., H1 2016 15
Left Ventricular Dysfunction - Pipeline by Innopharmax Inc., H1 2016 16
Left Ventricular Dysfunction - Pipeline by RedHill Biopharma Ltd., H1 2016 17
Left Ventricular Dysfunction - Pipeline by TiGenix NV, H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Left Ventricular Dysfunction Therapeutics - Recent Pipeline Updates, H1 2016 39
Left Ventricular Dysfunction - Dormant Projects, H1 2016 49
Left Ventricular Dysfunction - Discontinued Products, H1 2016 50

List of Figures
Number of Products under Development for Left Ventricular Dysfunction, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 10
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Targets, H1 2016 20
Number of Products by Stage and Targets, H1 2016 20
Number of Products by Mechanism of Actions, H1 2016 22
Number of Products by Stage and Mechanism of Actions, H1 2016 22
Number of Products by Routes of Administration, H1 2016 24
Number of Products by Stage and Routes of Administration, H1 2016 24
Number of Products by Molecule Types, H1 2016 26
Number of Products by Stage and Molecule Types, H1 2016 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glutamyl Aminopeptidase ...

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) ...

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘NADPH ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.